QDx Pathology to Market Mitomics' PCR-Based Mitochondrial DNA Prostate Cancer Test in US | GenomeWeb

Canadian molecular diagnostics firm Mitomics said today that it has entered into a non-exclusive licensing agreement with QDx Pathology to develop, market, and process a mitochondrial DNA test for determining the presence of malignant cells in normal-appearing prostate biopsies.

The test, which QDx Pathology will market under the name QPredict Prostate Mitomic Test, is based on Mitomics' currently marketed Prostate Core Mitomic Test, or PCMT.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.